We are honored to announce that Prof. Dr. Seza Özen who is the member of Honorary Advisory Board of JBACHS has already won the Aziz Sancar Science Award of TUSEB.
We are happy to announce that The Journal of Basic and Clinical Health Sciences (JBACHS) is indexed by the Emerging Sources Citation Index since November 2017, and indexed by the Ulakbim-TR since 2017.
Journal of Basic and Clinical Health Sciences 2019 , Vol 3 , Issue 3
Lu-177 PSMA I&T Therapy for Prostate Cancer; Treatment Response, Treatment Toxicity, and Survival Results
Emine Acar1,Burak Sönmezer3,Erkan Derebek3,Recep Bekiş3,Özhan Özdoğan3,Gamze Çapa Kaya3
1Izmir Katip Celebi University, Ataturk Education and Research Hospital, Department of Nuclear Medicine, İzmir, Turkey
2Dokuz Eylul University, Institute of Healh Sciences, Department of Translational Oncology, İzmir, Turkey
3Dokuz Eylul University, School of Medicine, Department of Nuclear Medicine, İzmir, Turkey
DOI : 10.30621/jbachs.2019.708 Purpose: This study aims to evaluate the serum PSA response, Ga-68 PSMA PET/CT response, hematological/nephrological toxicity and survival results of patients with castration-resistant metastatic prostate cancer who are receiving Lu-177 PSMA therapy.

Methods: The data of 57 patients with a mean age of 68 years who were treated with Lu-177 PSMA I&T were retrospectively reviewed. Secondary toxicity to treatment was determined using the criteria of the Common Toxicity Criteria for Adverse Events v5.0. The Kaplan Meier method was used for survival and progression-free survival analysis.

Results: Forty percent of patients" serum PSA values" showed >25% regression after the first cycle of treatment. Serum PSA values were stable/ regressed in 75% of the patients. While 2/57 patients showed grade 3 anemia, none showed grade 3 leukopenia or thrombocytopenia. One of 57 patient showed transient nephrotoxicity. Hematological and nephrological toxicity were not observed after treatment of eight cycles, and the serum PSA values of the patients were decreased by 97%. The mean survival time was 11.6 months in all patients, and 17.2 months in patients with serum PSA response. Progression-free survival was an average of 9.9 months.

Conclusion: Providing a stable or regressed disease via single cycle treatment in 75% of patients with progression despite the treatments improving survival is an indicator of the success of the therapy. The low rate of hematological and nephrological toxicity in patients (none of the patients that received eight cycles) suggests that the treatment is reliable. Survival was longer in patients with serum PSA response after treatment. Keywords : PSMA, prostate cancer, radioligand therapy, mCRPC, theranostic, precision medicine